Objective To construct a prediction model for targeted biopsy(TB)of the prostate based on multiparameter magnetic resonance imaging(mp-MRI)and prostate-specific antigen density(PSAD)to predict the outcomes TB in patients with a score of 4-5 on the Prostate Imaging Reporting and Data System(PI-RADS).Methods Clinical data of 669 patients with PI-RADS 4-5 receiving transperineal TB in our hospital during Jan.2022 and Dec.2023 were retrospectively analyzed.The data were divided into the training set and validation set with a ratio of 2∶1.Independent predictors of TB results were identified with univariate and multivariate logistic regression to construct a formula for the prediction model.A prediction model was subsequently constructed and validated using the validation set to assess its efficacy and predictive performance with the area under the receiver operating characteristic curve(AUC).The relative importance of each independent predictor in the formula was analyzed.Results Univariate and multivariate logistic regression analyses showed that age,total number of lesions,histological location,PI-RADS score and PSAD were significantly associated with the TB outcomes(P＜0.05)and could be used as independent predictors,with PI-RADS score and PSAD making the highest contribution to outcome prediction,accounting for 27.59％and 37.58％,respectively.The training set had an AUC of 0.840(95％CI:0.800-0.881),which was more predictive than other single predictors,and the high-risk group based on the optimal threshold of 0.833 increased the positive biopsy rate from 79.3％to 94.4％.The validation set had an AUC of 0.865(95％CI:0.810-0.920),and the high-risk group based on the optimal threshold of 0.594 increased the positive biopsy rate from 80.0％to 96.2％.Conclusion The prediction model has good predictive ability for lesions with PI-RADS 4-5,which can significantly improve the positive detection rate and reduce a large number of unnecessary systematic puncture.

Objective To construct a prediction model for targeted biopsy(TB)of the prostate based on multiparameter magnetic resonance imaging(mp-MRI)and prostate-specific antigen density(PSAD)to predict the outcomes TB in patients with a score of 4-5 on the Prostate Imaging Reporting and Data System(PI-RADS).Methods Clinical data of 669 patients with PI-RADS 4-5 receiving transperineal TB in our hospital during Jan.2022 and Dec.2023 were retrospectively analyzed.The data were divided into the training set and validation set with a ratio of 2∶1.Independent predictors of TB results were identified with univariate and multivariate logistic regression to construct a formula for the prediction model.A prediction model was subsequently constructed and validated using the validation set to assess its efficacy and predictive performance with the area under the receiver operating characteristic curve(AUC).The relative importance of each independent predictor in the formula was analyzed.Results Univariate and multivariate logistic regression analyses showed that age,total number of lesions,histological location,PI-RADS score and PSAD were significantly associated with the TB outcomes(P＜0.05)and could be used as independent predictors,with PI-RADS score and PSAD making the highest contribution to outcome prediction,accounting for 27.59％and 37.58％,respectively.The training set had an AUC of 0.840(95％CI:0.800-0.881),which was more predictive than other single predictors,and the high-risk group based on the optimal threshold of 0.833 increased the positive biopsy rate from 79.3％to 94.4％.The validation set had an AUC of 0.865(95％CI:0.810-0.920),and the high-risk group based on the optimal threshold of 0.594 increased the positive biopsy rate from 80.0％to 96.2％.Conclusion The prediction model has good predictive ability for lesions with PI-RADS 4-5,which can significantly improve the positive detection rate and reduce a large number of unnecessary systematic puncture.

Yersiniosis is one of the "other infectious diarrhea" of the notifiable infectious diseases and also an important food-borne disease. However, it lacked the basis or standard for diagnosis. The Chinese Preventive Medicine Association coordinated experienced researchers from National Institute for Communicable Disease Control and Prevention, China CDC and other institutes to produce the group standard entitled "Diagnosis of Yersiniosis" (T/CPMA 005-2019). Based on the principle of "legality, scientificity, advancement, and feasibility" , the standard gives a clear definition for Yerisiniosis, stipulates diagnosis basis, principles and main differential diagnosis and provides two informative appendixes for epidemiological and clinical characteristics and a normative appendix for laboratory detection. The standard provides accurate basis and methods of Yersiniosis diagnosis for hospitals and CDCs at all levels in China. It will solve the problems that Yersiniosis cannot be clearly diagnosed for clinical cases and in the outbreaks.

Background and objectiveTo compare the predictive effect of the Masaoka-Koga staging system and the International Association for the Study of Lung Cancer (IASLC)/the International Thymic Malignancies Interest Group (ITMIG) proposal for the new TNM staging on prognosis of thymic malignancies using the Chinese Alliance for Research in Thymomas (ChART) retrospective database.MethodsFrom 1992 to 2012, 2,370 patients in ChART database were ret-rospectively reviewed. Of these, 1,198 patients with complete information on TNM stage, Masaoka-Koga stage, and survival were used for analysis. Cumulative incidence of recurrence (CIR) was assessed in R0 patients. Overall survival (OS) was evalu-ated both in an R0 resected cohort, as well as in all patients (any R status). CIR and OS were ifrst analyzed according to the Masaoka-Koga staging system. Then, they were compared using the new TNM staging proposal.Results Based on Masaoka-Koga staging system, signiifcant difference was detected in CIR among all stages. However, No survival difference was revealed between stage I and II, or between stage II and III. Stage IV carried the highest risk of recurrence and worst survival. According to the new TNM staging proposal, CIR in T1a was signiifcantly lower comparing to all other T categories (P<0.05) and there is a signiifcant difference in OS between T1a and T1b (P=0.004). T4 had the worst OS comparing to all other T categories. CIR and OS were signiifcantly worse in N(+) than in N0 patients. Signiifcant difference in CIR and OS was detected between M0 and M1b, but not between M0 and M1a. OS was almost always statistically different when comparison was made between stages I-IIIa and stages IIIb-IVb. However, no statistical difference could be detected among stages IIIb to IVb.Conclusion Compared with Masaoka-Koga staging, the IASLC/ITMIG TNM staging proposal not only describes the extent of tumor invasion but also provides information on lymphatic involvement and tumor dissemination. Further study using prospectively recorded information on the proposed TNM categories would be helpful to better grouping thymic tumors for predicting prognosis and guiding clinical management.

Objective To investigate the efficacy and safety of different doses of aripirazole on hyperlactinemia induced by amisulpride and risperidone.Methods 87 patients with hyperlactinemia induced by amisulpride were randomly assigned to three groups on the basis of original medication combined with aripiprazole 5 mg/d,10 mg/d and 15 mg/d (Ami+5 mg,Ami+10 mg,Ami+15 mg) with 29 cases in each group.106 patients with hyperlactinemia induced by risperidone were randomly assigned to three groups on the basis of original medication combined with aripiprazole 5 mg/d (36 cases),10 mg/d (35 cases) and 15 mg/d (35 cases).The plasma prolactin (PRL) level was measured before and after 4th,8th and 12th week treatment.The Positive and Negative Syndrome Scale (PANSS) and Treatment Emergent Symptom Scale (TESS) were assessed for psychotic symptoms and adverse effects.Results The level of PRL of Ami+5 mg,Ami+ 10 mg and Ami+ 15 mg group had no statistical difference within and between groups at 4th,8th and 12th week.The level of PRL of Ris+5 mg,Ris+ 10 mg and Ris+ 15 mg group were significantly lower than that of baseline at each visit after baseline.The level of PRL of Ris+ 5 mg group ((38.9± 19.0) nmol/L vs.(11.0±8.1) nmol/L),Ris+ 10 mg group ((36.2± 16.5) nmol/L vs.(8.8±7.3) nmol/L) and Ris+ 15 mg group((35.6± 14.8) nmol/L vs.(9.2±7.6) nmol/L) at baseline were significantly different from which at the 12th week (t=4.129,4.798,4.506;all P＜0.01).The remission rates of symptoms relevant with hyperlactinemia in Ris+5 mg group,Ris+10 mg group and Ris+15 mg group were 66.67％ (24/36),62.86％ (22/35),51.43％ (18/35) respectively.There were no difference of the remission rate of symptoms relevant with hyperlactinemia among those three groups.There were no difference of PANSS score within groups at 12th week except Ami+ 15 mg group,Ris+ 10 mg group and Ris+ 15 mg group(t=2.419,2.406,2.631,all P＜0.05).The adverse effect rate of Ami+ 15 mg group (52％(15/29)) was significantly higher than that of Ami+5 mg group(17％(5/29),t=3.521,P＜0.01) and Ami+ 10 mg group (24％ (7/29),t=2.348,P＜0.05).The adverse effect rate of Ris+ 15 mg group (34％(12/35))was significantly higher than that of Ris+5 mg group (11％(4/36),t=2.203,P＜0.05) and Ris+ 10 mg group (11％ (4/35),t=2.314,P＜0.05).Conclusion Various dose of aripiprazole did not show improvement in hyperprolactinemia induced by amisulpride,However that could significantly decrease PRL level in hyperprolactinemia induced by risperidone,and considering efficacy and safety,5 mg/d aripirazole may be the best combination dose.

Objective To investigate the efficacy and safety of different doses of aripirazole on hyperlactinemia induced by amisulpride and risperidone.Methods 87 patients with hyperlactinemia induced by amisulpride were randomly assigned to three groups on the basis of original medication combined with aripiprazole 5 mg/d,10 mg/d and 15 mg/d (Ami+5 mg,Ami+10 mg,Ami+15 mg) with 29 cases in each group.106 patients with hyperlactinemia induced by risperidone were randomly assigned to three groups on the basis of original medication combined with aripiprazole 5 mg/d (36 cases),10 mg/d (35 cases) and 15 mg/d (35 cases).The plasma prolactin (PRL) level was measured before and after 4th,8th and 12th week treatment.The Positive and Negative Syndrome Scale (PANSS) and Treatment Emergent Symptom Scale (TESS) were assessed for psychotic symptoms and adverse effects.Results The level of PRL of Ami+5 mg,Ami+ 10 mg and Ami+ 15 mg group had no statistical difference within and between groups at 4th,8th and 12th week.The level of PRL of Ris+5 mg,Ris+ 10 mg and Ris+ 15 mg group were significantly lower than that of baseline at each visit after baseline.The level of PRL of Ris+ 5 mg group ((38.9± 19.0) nmol/L vs.(11.0±8.1) nmol/L),Ris+ 10 mg group ((36.2± 16.5) nmol/L vs.(8.8±7.3) nmol/L) and Ris+ 15 mg group((35.6± 14.8) nmol/L vs.(9.2±7.6) nmol/L) at baseline were significantly different from which at the 12th week (t=4.129,4.798,4.506;all P＜0.01).The remission rates of symptoms relevant with hyperlactinemia in Ris+5 mg group,Ris+10 mg group and Ris+15 mg group were 66.67％ (24/36),62.86％ (22/35),51.43％ (18/35) respectively.There were no difference of the remission rate of symptoms relevant with hyperlactinemia among those three groups.There were no difference of PANSS score within groups at 12th week except Ami+ 15 mg group,Ris+ 10 mg group and Ris+ 15 mg group(t=2.419,2.406,2.631,all P＜0.05).The adverse effect rate of Ami+ 15 mg group (52％(15/29)) was significantly higher than that of Ami+5 mg group(17％(5/29),t=3.521,P＜0.01) and Ami+ 10 mg group (24％ (7/29),t=2.348,P＜0.05).The adverse effect rate of Ris+ 15 mg group (34％(12/35))was significantly higher than that of Ris+5 mg group (11％(4/36),t=2.203,P＜0.05) and Ris+ 10 mg group (11％ (4/35),t=2.314,P＜0.05).Conclusion Various dose of aripiprazole did not show improvement in hyperprolactinemia induced by amisulpride,However that could significantly decrease PRL level in hyperprolactinemia induced by risperidone,and considering efficacy and safety,5 mg/d aripirazole may be the best combination dose.

Objective To explore effects of Naikan cognitive therapy on improving clinical symptoms in patients with convalescent schizophrenia. Methods The 69 convalescent schizophrenic patients with convalescent clinical state were consecutively recruited. All the patients were divided into Naikan cognitive therapy ( NCT) group an control group at random and were pretreated with antipsychotic agent therapy. In NCT group,the patients received NCT for successive 7 days. In control group,the patients only received antipsychotic agent therapy. Pre-and post-treatment positive and negative syndrome scale( PANSS) , Nurses'observation scale for inpatient evaluation (NOSIE) were administered to all subjects. Results ① A significant decrease occurred in PANSS total score, negative symptom score, positive symptom score, compound scale score, general psychopathology score, reaction retardation score and paranoid score in NCT group ( t = 2. 672～7. 370, P < 0. 05). In the post-treatment, PANSS total score, negative symptom score, positive symptom score, compound scale score, reaction retardation score and thought disorder score were significantly lower in NCT group than those in control group ( t ' = 2. 696, P = 0. 009; t = 5. 186, P=0.000; t = 3.757, P = 0.001; t = 2.634,P = 0.011; t ' =2.376, P = 0.021). ②A significant decrease occurred in NOSIE total negative score( 10.43 ± 9. 24 vs 13. 87 ± 8. 03, t = 3. 463 , P = 0. 002) , irritation score(3. 13 ±0.43 vs8.53 ±4.98, t = 6. 139, P=0.000) and retardation score(1.07 ± 1.64 vs 2. 20 ±2.85, t = 2.067, P = 0.048) in NCT group. Conclusion NCT can possibly improve part clinical symptoms of patients with convalescent schizophrenia to a certain extent,especially negative symptom,but need to further prove the effect of NaiKan cognitive therapy.

Objective: To observe the anti- arrhythmic effects of Lvfukang Capsules on the experimental arrhythmic models induced by aconitine in rats, and provid accordance for clinical medication. Methods: 50 rats were divided into model control group, positive control group, high, middle and low dosage groups of Lvfukang Capsules, respectively. All the dosage groups were treated with successive medication 3 days, arrhythmic models induced by aconitine for 30minutes after the last dosage. To observe and record the time of ventricular premature beat (VP) and ventricular fibrillation (VF). Results: All the dosage groups of Lvfukang Capsules significantly delayed the time of ventricular premature beat (VP) and ventricular tachycardia (VT) of arrhythmic models of rats (P